White Paper

Securing Operational Technology in Medical Manufacturing

Life Sciences Updated 2026-02-19 12 min read

Executive Summary

In June 2025, the FDA released a white paper on securing the operational technology used to make medical products. It arrived as manufacturing became the most attacked critical-infrastructure sector, ransomware activity climbed, and pharmaceutical data breaches reached among the highest average costs of any industry. Recent incidents at West Pharmaceutical Services and Novo Nordisk show the sector is being targeted directly.

The stakes are specific to life sciences. In a regulated manufacturing environment, a cyberattack can become a patient-safety and supply-stability event, and production cannot simply restart afterward because every system change has to be documented and revalidated first. The FDA's message is that you can design a secure device and still put patients at risk if it is produced in a compromised facility.

This guide translates the FDA's white paper into practical steps for CIOs, CISOs, and quality leaders. It covers what the paper is and is not, the three areas the FDA asks you to focus on, the hard tension between fast patching and GxP validation, and a first-90-days plan you can act on. People-First. AI-Amplified.

Download the full PDF for the complete analysis, frameworks, and implementation guidance.

Key Takeaways

  • The FDA paper is a signal, not a mandate. It fills the gap between device cybersecurity guidance and the manufacturing environment where medical products are made.
  • Operational technology was built for reliability, not security. Controllers and connected equipment often ship without meeting recognized cybersecurity standards.
  • The FDA organizes its recommendations into three areas: technical information exchange (visibility and SBOMs), security standards and compliance (NIST, FIPS 140-2/3, CISA), and security by design (segmentation, access control, monitoring).
  • The hard part is the GxP tension. Fast patching collides with change control and revalidation, so a risk-based approach with compensating controls is essential.
  • A workable first 90 days: asset inventory, request SBOMs, segment OT from IT and the internet, tighten access, add OT monitoring, map controls to standards, and validate an incident-response plan.

Ready to assess your security?

Take the 2-minute assessment to see where you stand.

Take the Assessment

More Life Sciences Resources

White Paper

The Invisible Threat to Innovation

How cyber risks silently erode R&D pipelines, supply chain integrity, and financial stability in life sciences — and why leadership teams need visibility now.

Read preview →
White Paper

Optimizing Security & Operational Efficiency

A framework for balancing rigorous cybersecurity with the operational agility life sciences organizations need to innovate and grow.

Read preview →
White Paper

The ROI of Proactive Cybersecurity

How to build the business case for cybersecurity investment — with ROI frameworks, cost-of-inaction analysis, and partner evaluation criteria.

Read preview →
White Paper

Securing the Future of Life Sciences

Protecting IP, funding, and regulatory milestones from cyber threats — a strategic overview for life sciences executives navigating an evolving threat landscape.

Read preview →
White Paper

Strategic Cybersecurity for Executives

Balancing innovation, compliance, and investor confidence — a framework for life sciences executives to integrate cybersecurity into strategic planning.

Read preview →
White Paper

De-Risking Your Investment

How a strategic cybersecurity assessment fuels funding and regulatory success — making the case for proactive security investment in life sciences.

Read preview →
White Paper

Safeguarding Innovation

Advanced cybersecurity strategies for IP protection in life sciences — defending proprietary research, formulations, and clinical data from sophisticated threats.

Read preview →
White Paper

AI Readiness for Life Sciences

Navigating the cybersecurity risks and compliance challenges of AI adoption in life sciences — from data governance to model security.

Read preview →
Checklist

Regulatory Audit Readiness

Comprehensive guide for life science executives preparing for regulatory audits — covering HIPAA, FDA, GxP, and international compliance requirements.

Read preview →
Checklist

Cybersecurity Readiness Checklist

Innovation safeguard self-assessment for life science firms — evaluate your cybersecurity posture across the areas that matter most to research-driven organizations.

Read preview →

You Call. We Answer. It Works.

No pressure, no obligation. Just a conversation about where your technology stands and where you want it to go. Your free assessment takes two minutes.

Get Your Free Assessment Call (619) 651-8700